close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ipsen Pharma

< Previous 1 2 Next >
News headline image
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen appoints Keira Driansky as EVP, President of North America
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
From Ipsen Pharma
Via GlobeNewswire
News headline image
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
From Ipsen Pharma
Via GlobeNewswire
News headline image
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
From Ipsen Pharma
Via GlobeNewswire
News headline image
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen updates on QM-1114 regulatory process
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
From Ipsen Pharma
Via GlobeNewswire
News headline image
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
From Ipsen Pharma
Via GlobeNewswire
News headline image
US FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen delivers solid H1 2023 results and upgrades its full-year guidance
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights - effective from December 19, 2023
From Ipsen Pharma
Via GlobeNewswire
News headline image
Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen announces European Commission decision on palovarotene for the treatment of FOP
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
From Ipsen Pharma
Via GlobeNewswire
News headline image
Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva
From Ipsen Pharma
Via GlobeNewswire
News headline image
Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma
From Ipsen Pharma
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today